Axalta Coating Systems Group has completed the acquisition of André Koch, a well-established provider of car repair and maintenance services. André Koch, previously privately owned, has excelled in the premium segment of the refinish market
Tags :Lucas Maurer
In a groundbreaking move, Boehringer Ingelheim has sealed the deal to acquire T3 Pharmaceuticals, a dynamic Swiss biotech company, for a staggering amount of up to 450 million CHF. This strategic move signals a major leap
Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, has announced the completion of its oversubscribed Series C equity financing raising €67.5 million ($72 million) from a syndicate of renowned
Over the past years, Capture Media has played a significant role in shaping the landscape of Engagement Advertising in Switzerland, becoming an essential quality factor for many online campaigns. The company has also introduced fusedeck,
CONVOTIS has acquisted JMC Group and is entering the Swiss IT market as a platform company and strengthening its position in the managed services and digital platform solutions segment. This acquisition not only provides an
Vischer acted as legal advisor to LimmaTech Biologics as it successfully concluded a USD 37 million (CHF 33 million) Series A financing round, co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund.
Pierre Fabre Laboratories, the French pharmaceutical and dermo-cosmetic company, announced the acquisition of Vertical Bio, a a biotechnology company developing a novel antibody to treat certain forms of cancer. Vertical Bio was founded by Versant
Walder Wyss advises Swiss biotech Alentis Therapeutics in connection with their USD 105m Series C funding to support the development of its lead assets. The funding round was led by Jeito Capital together with Novo
Walder Wyss has advised BC Platforms, an expert of data science solutions for personalized healthcare, drug discovery and life science research, in connection with the CHF 20 million (approx. USD 20 million) growth financing round. This growth
The Swiss pharmaceutical BioVersys has raised CHF 24.2 million in a first closing of its Series C round. This first closing was significantly oversubscribed by both existing and new investors from diverse geographies. The company intends
